Clinical review report: Tenofovir alafenamide (Vemlidy) (Gilead Sciences Canada, Inc.)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tenofovir alafenamide for the treatment of adults with chronic hepatitis B (CHB) and compensated liver disease
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
April 2018, 2018
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tenofovir alafenamide for the treatment of adults with chronic hepatitis B (CHB) and compensated liver disease |
|---|---|
| Physical Description: | 1 PDF file (65 pages) illustrations |